Google found a way to make virtual meetings suck less
Now, Starline is nearly ready for primetime. It's being rebranded to Google Beam and coming to a handful of offices later this year. Google has managed to shrink the technology into something it says will be priced comparably to existing videoconference systems. The real bet is that other companies will want to make their own hardware for Beam calls. 'The devices aren't really the point,' says Andrew Nartker, the project's general manager. 'The point is that we can beam things anywhere we need to with the infrastructure that we built.'
Beam uses a light field display and six cameras to render a volumetric, real-time 3D version of the person on the other end of a videocall. There's no headset, no weird glasses. Just a chunky display, a Chrome OS-powered compute puck the size of a DVD player, and a bespoke AI model working with Google Cloud in the background to stitch it all together. Google has created a reference design for manufacturers, starting with HP, to make into their own hardware.
I used Beam during a demo at Google's campus the day before its annual I/O conference, where AI is once again taking center stage. Beam wasn't something originally designed for the modern AI boom, but its trajectory has been impacted by it. I was shown the earliest prototype that filled a small room and relied fully on local computing. Over the last couple of years, Google moved the vast majority of that horsepower to the cloud via a custom AI video model, which paved the way for the simpler, cheaper hardware design that HP is now using.
The pricing and availability details for HP's Google Beam device are coming next month. Google says that Salesforce, Deloitte, Duolingo, and a handful of other companies have committed to installing units in their offices. Its video model takes a couple of milliseconds to process all the data — one stereo video stream for each eye, captured by six standard-color cameras — over typical office internet. T-Mobile even tested it over LTE once. (I noticed some lag a couple of times during my demo at Google's headquarters.)
While developing Beam, Google observed that people feel a real 'fatigue' from regular, 2D virtual meetings. 'We've done rigorous studies that show people feel a stronger sense of attentiveness' after using Beam, says Jason Lawrence, its head of engineering and research. 'They remember more of their conversations. They tend to be more animated. We see more nonverbal behaviors.'
Those subtle cues may feel insignificant, but they add up when you experience Beam for more than a couple of minutes. I found myself wanting to physically lean into conversations. Being able to make eye contact with the other person gave a feeling of presence that you can't get through a traditional webcam. Calls on the latest AI model paired with the commercial, HP-made hardware for Beam are noticeably richer. Colors pop more, and the spatial audio sounds dramatically better than Google's in-house prototypes.
With the hardware in a better place, Google is now focused on making Beam a real alternative to Zoom or Meet. I was shown a new screen-mirroring feature that placed a browser window to the side of whoever I was looking at, and another call demonstrated live translation from Spanish to English. Beam is limited to one-on-one calls for now, though group calling is coming, along with the ability to display regular, 2D video calls.
Nartker says the long-term vision is to bring Beam into homes and not just offices. 'We're going to build a bunch of devices,' he says. For now, though, Beam is another Google moonshot taking its first step into reality — one that might make remote meetings marginally less painful.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
28 minutes ago
- Wall Street Journal
Unemployed Americans Endure Longer Job Searches in a Cooling Market
Job seekers are out in the cold this summer. Especially the ones who have been hunting for a while. Beyond the headline-grabbing top-line numbers in the jobs report for July was another striking piece of data: The number of people unemployed for at least 27 weeks topped 1.8 million, the highest level since 2017, not counting the pandemic's unemployment surge. The median length of unemployment in the U.S. has also ticked up, from a seasonally adjusted 9.5 weeks in July 2024 to 10.2 weeks last month.
Forbes
28 minutes ago
- Forbes
Trump Says He Will Get Drug Prices Down By 1500%
U.S. President Donald Trump is now promising to get pharmaceutical companies to significantly reduce the drug prices that they are charging Americans. On Thursday, the White House announced that Trump had just sent letters to the heads of 17 major pharmaceutical companies pushing them to cut the prices that Americans have to pay down to the levels that people in other countries pay. It's not clear yet by what amount—if any—this will eventually get pharmaceutical companies to reduce prescription medication prices for those in the U.S. But chances are any price reductions that end up occurring won't be anywhere near the 1500% that Trump has promised. Trump Spoke Of 600%, 1000% And 1500% Reductions in Drug Prices Yep, 1500% is the percentage that Trump mentioned in a July reception with members of Congress. 'This is something that nobody else can do,' Trump emphasized then. "We're gonna get the drug prices down. Not 30 or 40 percent, which would be great, not 50 or 60, no. We're gonna get 'em down 1,000 percent, 600 percent, 500 percent, 1,500 percent.' Here's a video of this posted on what used to be Twitter: Getting the prices of medications—or of anything that's sold by companies for that matter—down by more than 100% is certainly something that no one else has done. It's probably something you have never even dreamed of before, since for-profit companies are usually trying to make, you know, a profit. So, it's kind of true what Trump then subsequently said, 'We will have reduced drug prices by 1,000 percent, by 1,100, 1,200, 1,300, 1,400, 700, 600; not 30 or 40 or 50 percent but numbers the likes of which you've never even dreamed of before.' A video of this was also posted on X: Let's do the math. Say a bottle of a medication currently costs $100. A 25% price reduction would bring this cost down to $75. A 100% price reduction would make the medication completely free. Any reduction greater than 100% would presumably mean that the manufacturer would have to pay you. Thus, a 200% price reduction would result in a $100 payday per bottle for you. Holy, new way to earn money, Batman! If Trump can get you a 1500% reduction, hallelujah, time to replace filming YouTube videos with 'buying' medications as the way to make money. Now, the chances that the Trump administration will achieve a 1500% reduction in drug prices are probably a whole lot less than 100%. Getting pharmaceutical companies who have been enjooying very healthy profits for years to pay customers to take their drugs would be quite a trick. Plus, the pharmaceutical companies would have to change their advertisements so that instead of telling you that you may have a condition that you don't realize you have, the ads might say something like 'You're fine and don't have anything that pharmaceutical interventions can't fix. Please don't use our medications. We can't afford you to do so.' Trump Sent Letters To 17 Pharmaceutical Companies Outlining Steps To Reduce Drug Prices That 1500% number may not have been in the letters that Trump sent on Thursday to pharmaceutical manufacturers. Assuming that the letters had the right postage, they went to the leaders of AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi. According to the White House, the letters listed steps to reduce the prices of prescription drugs in the U.S. 'to match the lowest price offered in other developed nations (known as the most-favored-nation, or MFN, price)' The steps are as follows: The letters asserted that there's been 'global freeloading on American pharmaceutical innovation' and did warn that if the outlined steps were't taken by the pharmaceutical companies the federal government "will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices." Trump Signed An Executive Order Regarding Drug Prices In May Pharmaceutical companies can now be 1500% sure that the Trump administration has them in its political line-of-sight. Back on May 12, Trump signed an Executive Order that asserted the following: 'The United States has less than five percent of the world's population and yet funds around three quarters of global pharmaceutical profits. This egregious imbalance is orchestrated through a purposeful scheme in which drug manufacturers deeply discount their products to access foreign markets, and subsidize that decrease through enormously high prices in the United States.' That Executive Order indicated that the U.S. Secretary of Health and Human Services, which is currently Robert F. Kennedy, Jr., 'shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation price.' Americans Do Pay Higher Drug Prices Than Those In Other Countries It is true that drug prices are typically significantly higher in the U.S. than in other countries. For example, a June 2024 publication in the RAND Health Quarterly described how drug prices in the U.S. were on average nearly three times higher than those in 33 other high-income countries. Over the past two decades, yearly rises in drug prices have easily outpaced inflation. A 2024 KFF poll showed that the majority of Americans are worried about prescription medication costs being too high. Such worries shouldn't be that surprising. Many prescription medications are not like mullets or fruitcakes. Taking them is often not a choice. Your well-being and even your life could literally depend on being able to afford the medication. And many pharmaceutical companies have shown no qualms about raising the price of medications as soon as they can. For example, even after receiving substantial funding from the U.S. government, Pfizer and Moderna quickly raised the prices of their COVID-19 vaccines as soon as the government wouldn't completely pay for them, as I described in Forbes in 2023. It is also true that talk about drug prices being too high in the U.S. is not new. Yet, none of the Presidential Administrations over the past two decades have done much to significantly alter these trends. I've written about state-wide efforts to reduce drug prices, such as Propostion 61 in California. But there's been a lack of more comprehensive efforts at the federal level to do so. The challenge is that a number of trends in the current U.S. system are contributing to higher drug prices. For example, mergers and acquisitions over the years have led to fewer, larger and more dominant pharmaceutical companies with less competition. Existing cost structures and requirements make it more difficult for new pharmaceutical companies to emerge and provide more competition. Cuts in funding and support for scientific research has made it harder and harder to develop new products. Fewer new products leave patients with fewer alternatives and existing products with less competition. Consumers and different purchasers have lacked negotiating power in general. At the same time, it seems like more and more people have been getting pieces of the drug price pie. This has included various middle people such as pharmacy benefits managers and different administrators. The marketing budgets of pharmaceutical companies have continued to grow as well. On top of that, investors have expected pharmaceutical companies to have ever increasing profitability. All of this means that a single simple intervention probably has a small percentage chance of reducing drug prices in a sustainable manner. Instead, a system approach may be needed, meaning multiple interventions at different points in the system that work together in a coordinated manner. Otherwise, there may be unintended consequences. A sustainable reduction in drug prices means one in which the math works out for all patients. You don't want a situation where the prices of some drugs are reduced while those of others are raised. You also don't want a situation where the costs end up being hidden.
Yahoo
44 minutes ago
- Yahoo
Trump fires Bureau of Labor Statistics commissioner after weak jobs report
The president fired the commissioner on Friday after a weaker-than-expected July jobs report showed hiring slowed with only 73,000 new jobs created, and revisions revealed hiring in May and June was much less than initially reported.
